Small molecule inhibitors as a new approach to study human RAD51 recombinase
小分子抑制剂作为研究人类 RAD51 重组酶的新方法
基本信息
- 批准号:9762019
- 负责人:
- 金额:$ 35.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAnimal ModelApoptosisBase Excision RepairsBiochemicalBiologicalBiological AssayBiologyBiophysicsCancer PatientCell Cycle CheckpointCell SurvivalCell modelCell physiologyCellsChickensCollectionCombined Modality TherapyComplementComplexCruciform DNACrystallographyDNADNA DamageDNA Double Strand BreakDNA RepairDNA Repair PathwayDNA biosynthesisDNA lesionDevelopmentDockingDoseGenetic DiseasesGenomic InstabilityGoalsHealthcareHomologous ProteinHumanIn VitroIndividualKnowledgeMeasuresModernizationMolecularMusMutateMutationNamesNonhomologous DNA End JoiningNormal CellOrganismPathway interactionsPlayProliferatingPropertyProteinsRad51 recombinaseRadiationRadiation therapyRadioReactionRoleSpecificityStructureTherapeuticTherapeutic AgentsTimeXenograft procedureanalogcancer cellcancer geneticscancer therapycell killingcellular developmentchemotherapeutic agentchemotherapycombination cancer therapycrosslinkexperimental studygenetic approachhigh throughput screeninghomologous recombinationimprovedin vivoinhibitor/antagonistmigrationmutantnovelnovel strategiesprotein functionprototypepublic health relevancerepairedresponsesmall moleculesmall molecule inhibitortooltumor
项目摘要
DESCRIPTION (provided by applicant): The homologous recombination (HR) pathway plays a critical role in the repair of the most harmful DNA lesions, DNA double-strand breaks (DSB) and inter-strand cross-links (ICL). Malfunction of HR causes genome instability, cancer, and genetic diseases. RAD51, a key HR protein, promotes DNA strand exchange, a basic step of HR. However, the mechanism of DNA strand exchange and specific functions of RAD51 in human cells remain to be elucidated. Traditional genetic approaches are difficult to apply because RAD51 is essential for cell viability. Here, we propose to develop small molecule inhibitors to study RAD51 activities and functions. These inhibitors may also be used as prototypes for development of combination therapies to sensitize cancer cells for radiation and chemotherapy. Because millions of cancer patients commonly undergo radiation therapy and chemotherapy, improvement of their efficacy will have a significant impact on the public healthcare. Small molecule compounds (MW < 500 Da) that can perturb specific functions of proteins became an important tool in modern biology. Small molecule inhibitors act rapidly and often reversibly. They can be introduced at any point of organism or cell development and applied in a dose-dependent manner, which is especially important in studies of proteins essential for cell viability, like RAD51. Previously, by high throughput screening we identified several small molecule inhibitors of RAD51 and demonstrated for the first time their biological activity in the cell. Here, we will use these inhibitors to analyze the mechanism of RAD51 DNA strand exchange and the functions of RAD51 in human cells. Using cellular and animal models we will explore the ability of the RAD51 inhibitors alone or in combination with inhibitors of othe DNA repair pathways to increase killing of cancer cells by chemotherapeutic agents.
描述(由申请人提供):同源重组(HR)途径在修复最有害的DNA损伤、DNA双链断裂(DSB)和链间交联(ICL)中起关键作用。HR的功能障碍会导致基因组不稳定、癌症和遗传疾病。RAD51是一种重要的HR蛋白,它促进DNA链交换,这是HR的一个基本步骤,然而,DNA链交换的机制以及RAD51在人类细胞中的具体功能仍有待阐明。传统的遗传学方法很难应用,因为RAD51对细胞活力至关重要。在此,我们建议开发小分子抑制剂来研究RAD 51的活性和功能。这些抑制剂也可用作开发联合疗法的原型,以使癌细胞对放射和化学疗法敏感。由于数以百万计的癌症患者通常接受放射治疗和化学治疗,提高其疗效将对公共医疗产生重大影响。分子量小于500 Da的小分子化合物可以干扰蛋白质的特定功能,已成为现代生物学研究的重要工具。小分子抑制剂作用迅速且通常可逆。它们可以在生物体或细胞发育的任何点引入,并以剂量依赖性方式应用,这在细胞活力所必需的蛋白质(如RAD 51)的研究中尤其重要。此前,通过高通量筛选,我们鉴定了几种小分子的RAD51抑制剂,并首次证明了它们在细胞中的生物活性。在此,我们将使用这些抑制剂来分析RAD51 DNA链交换的机制以及RAD51在人类细胞中的功能。使用细胞和动物模型,我们将探索单独或与其他DNA修复途径的抑制剂组合的RAD51抑制剂增加化疗剂对癌细胞的杀伤的能力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALEXANDER V MAZIN其他文献
ALEXANDER V MAZIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALEXANDER V MAZIN', 18)}}的其他基金
Small Molecule inhibitors as a new approach to study human RAD51 recombinase
小分子抑制剂作为研究人类 RAD51 重组酶的新方法
- 批准号:
10396746 - 财政年份:2021
- 资助金额:
$ 35.81万 - 项目类别:
Mechanisms of RNA-dependent DNA repair in humans
人类 RNA 依赖性 DNA 修复机制
- 批准号:
10396741 - 财政年份:2020
- 资助金额:
$ 35.81万 - 项目类别:
Mechanisms of RNA-dependent DNA repair in humans
人类 RNA 依赖性 DNA 修复机制
- 批准号:
10576319 - 财政年份:2020
- 资助金额:
$ 35.81万 - 项目类别:
Mechanisms of RNA-dependent DNA repair in humans
人类 RNA 依赖性 DNA 修复机制
- 批准号:
10347369 - 财政年份:2020
- 资助金额:
$ 35.81万 - 项目类别:
Small molecule inhibitors as a new approach to study human RAD51 recombinase
小分子抑制剂作为研究人类 RAD51 重组酶的新方法
- 批准号:
8888191 - 财政年份:2015
- 资助金额:
$ 35.81万 - 项目类别:
Small molecule inhibitors as a new approach to study human RAD51 recombinase
小分子抑制剂作为研究人类 RAD51 重组酶的新方法
- 批准号:
9150646 - 财政年份:2015
- 资助金额:
$ 35.81万 - 项目类别:
Identification of inhibitors of RAD54, an important DNA repair protein
重要 DNA 修复蛋白 RAD54 抑制剂的鉴定
- 批准号:
8262294 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
Development of RAD52 Inhibitors to Induce Lethality of BRCA2-Deficient Cells
开发 RAD52 抑制剂以诱导 BRCA2 缺陷细胞致死
- 批准号:
8441581 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




